Implants lower IOP, reduce medication

Article

Implanatation of multiple trabecular micro-bypass implants (iStent, Glaukos) in Schlemm's canal following phamoemulsification successfully and significantly reduced IOP for 12 months after implantation, as well as the number of medications required to maintain target IOP

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
A binder labeled "2025 protocol" sits on a pile of papers, graphs and information. Concept image for glaucoma consensus group and interventional glaucoma research findings. Image credit: ©sasirin pamai via Canva.

A new set of guidelines for implementing interventional glaucoma

Hattie Hayes
June 24th 2025
Article

The framework covers ocular hypertension to severe progression

A small icon pinpoints a particular location on a map. Concept image for article titled "pinpointing a first-line treatment for glaucoma." Ophthalmology article, glaucoma laser treatment concept. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Pinpointing a first-line treatment for glaucoma

José María Martínez de la Casa, MD
June 3rd 2025
Article

Laser surgery is an appropriate adjunctive therapy across the continuum of glaucoma care, as well as a safe option for patients who also have cataracts and other complicating factors

An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

Research indicates B vitamins and choline provide neuroprotection against glaucoma

Lynda Charters
May 26th 2025
Article

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

Rethinking race as a risk factor for glaucoma

Rethinking race as a risk factor for glaucoma

M. Roy Wilson, MD, MS
April 9th 2025
Article

Social determinants of health challenge our existing expectations

A close-up of an elderly patient's face. They are administering eye drops. Image credit: ©photocrew – stock.adobe.com

Nicox SA shares research findings from NCX 470 Mont Blanc Phase 3 glaucoma trial

Jordana Joy
March 7th 2025
Article

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

The Voyager Direct Selective Laser Trabeculoplasty device. Image courtesy of Alcon.

Alcon launches Voyager direct selective laser trabeculoplasty device in the US

Sheryl Stevenson
February 21st 2025
Article

Voyager DSLT is already available in select markets in the EU and the UK, and reduces the specialised training required with manual selective laser trabeculoplasty

© 2025 MJH Life Sciences

All rights reserved.